Depression

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

Daniel Morehead, MD, critiques the discourse around antidepressants, urging a balanced view of their benefits and risks while addressing patient concerns.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

What is the hidden mental health struggles of affluent youth? In this Tales From the Clinic article, we reveal how wealth can contribute to anxiety, depression, and substance misuse.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Neurosurgeon Brian Kopell, MD, discusses the potential of deep brain stimulation for treatment-resistant depression, aiming to reduce stigma and improve patient care.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

New findings from the RESTORE-LIFE study suggest the potential benefits of VNS treatment in patients with DTD.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

Here are 10 things to consider when treating a patient with mood disorders.

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.